About
Oncobit AG is a Swiss MedTech company that specializes in precision diagnostic and monitoring solutions for personalized cancer care, focusing primarily on melanoma. The company develops genomic-based assays utilizing advanced technologies such as next-generation sequencing (NGS) and digital PCR, along with proprietary automated software for data analysis and reporting. Their main offering is a scalable cancer monitoring platform that detects cancer markers in liquid biopsies, allowing for precise tracking of cancer progression and therapy management. Oncobit’s flagship product is a CE-marked in-vitro diagnostic test that specifically identifies BRAFV600 mutations in liquid biopsy samples. This enables robust mutation tracking during treatment. The company collaborates with leading cancer centers in Europe and the US to promote the clinical adoption of its solutions and operates an ISO 15189 conform laboratory. Founded by a team of experts from the University Hospital Zurich and ETH Zurich, Oncobit is led by CEO Dr. Claudia Scheckel, who brings extensive experience in biomedical research. The company aims to enhance personalized cancer care through improved monitoring tools.
Technologies
Keywords
Company Information
-
Employees 12
-
Founded 2018
-
Total Funding $4189084
Location
16 Ruetistrasse, Schlieren, Zurich, Switzerland, 8952
